medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-18-8-12medsovet-2025Research ArticleХроническая обструктивная болезнь легкихChronic obstructive pulmonary diseaseБРОНХОПРОТЕКТИВНЫЙ ЭФФЕКТ ГЛИКОПИРРОНИЯ БРОМИДА У БОЛЬНЫХ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХBRONCHOPROTECTIVE EFFECT OF GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASEТрофименкоИ. Н.TrofimenkoI. N.

 д.м.н.

MD

ГуноваМ. В.GenovaM. V.ЧернякБ. А.ChernyakB. A.

д.м.н., профессор

MD, Prof

Иркутская государственная медицинская академия последипломного образования Минздрава РоссииРоссияIrkutsk State Medical Academy of Postgraduate Education of the Ministry of Health of RussiaRussian FederationНегосударственное учреждение здравоохранения «Дорожная клиническая больница на ст. Иркутск-пассажирский» ОАО «РЖД»РоссияNon-State Healthcare Institution Road Clinical Hospital at the station Irkutsk-Passazhirsky of JSC RZDRussian Federation201703112017018812Copyright © Трофименко И.Н., Гунова М.В., Черняк Б.А., 20172017Трофименко И.Н., Гунова М.В., Черняк Б.А.Trofimenko I.N., Genova M.V., Chernyak B.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2025

Бронхиальная гиперреактивность (БГР) является одной из функциональных характеристик хронической обструктивной болезни легких (ХОБЛ) и присутствует у большинства больных с этим заболеванием. БГР оказывает негативное модифицирующее влияние на эволюцию ХОБЛ, способствуя неблагоприятному прогнозу и повышенной летальности по сравнению с пациентами без гиперреактивности бронхов. Результаты оценки влияния гликопиррония бромида (ГБ) на БГР демонстрируют выраженный бронхопротективный эффект бронхолитика. На фоне терапии ГБ отмечается снижение уровня БГР (р < 0,05), сопровождающееся значительным уменьшением выраженности симптомов ХОБЛ, улучшением толерантности к физической нагрузке и показателей качества жизни больных в сравнении с исходными параметрами (р < 0,05). Таким образом, БГР при ХОБЛ представляется важным критерием терапевтической эффективности, а снижение уровня гиперреактивности бронхов оказывает существенное клиническое влияние на течение заболевания.

 

Bronchial hyperreactivity (BHR) is one of the functional characteristics of chronic obstructive pulmonary disease (COPD) and is present in most patients with this disease. BHR has a negative modifying effect on the development of COPD, contributing to adverse prognosis and increased mortality compared to patients without bronchial hyperresponsiveness. The results of the evaluation of the impact of glycopyrronium bromide (GB) on BHR show a pronounced effect of the bronchoprotective broncholytic. The therapy by GB results in decrease in the level of BHR (p < 0.05), accompanied by a significant reduction of symptoms of COPD, improves tolerance to exercise and quality of life of patients in comparison with initial parameters (p < 0.05). Thus, BHR in patients with COPD appears to be an important criterion of therapeutic efficacy and decrease of the level of bronchial hyperresponsiveness has a significant clinical impact on the course of the disease.

 

хроническая обструктивная болезнь легкихбронхиальная гиперреактивностьгликопиррония бромидбронхопротективный эффектchronic obstructive pulmonary diseasebronchial Hyper-reactivityglycopyrrolate bromidebronchoprotective effectReferencesGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org.Deesomchok A, Webb KA, Forkert L, Lam YM, Ofir D, Jensen D et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD, 2010, 7(6): 428-437.Deesomchok A, Webb KA, Forkert L, Lam YM, Ofir D, Jensen D et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD, 2010, 7(6): 428-437.Santus P, Radovanovic D, Henchi S, Di Marco F, Centanni S, D’Angelo E et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir. Physiol. Neurobiol., 2014, 15: 36-45.Santus P, Radovanovic D, Henchi S, Di Marco F, Centanni S, D’Angelo E et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir. Physiol. Neurobiol., 2014, 15: 36-45.Chapman KR, Beeh KM, Beier J, Bateman ED, D’Urzo A , Nutbrown R et al. A blinded evaluation of the efficacy and safety of glycopyrroni-um, a once-daily longacting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med., 2014. 14: 4.Chapman KR, Beeh KM, Beier J, Bateman ED, D’Urzo A , Nutbrown R et al. A blinded evaluation of the efficacy and safety of glycopyrroni-um, a once-daily longacting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med., 2014. 14: 4.Трофименко И.Н., Черняк Б.А. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Пульмонология, 2011, 4: 49-53.Трофименко И.Н., Черняк Б.А. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Пульмонология, 2011, 4: 49-53.Garcia-Aymerich J, Agustí A, Barberà JA, Belda J, Farrero E, Ferrer A et al. Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch. Bronconeumol., 2009, 45(3): 133-142.Garcia-Aymerich J, Agustí A, Barberà JA, Belda J, Farrero E, Ferrer A et al. Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch. Bronconeumol., 2009, 45(3): 133-142.Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10: 1155-1161.Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10: 1155-1161.Трофименко И.Н., Черняк Б.А. Предикторы тяжелой одышки у больных хронической обструктивной болезнью легких средней степени тяжести. Пульмонология, 2014, 2: 55-59.Трофименко И.Н., Черняк Б.А. Предикторы тяжелой одышки у больных хронической обструктивной болезнью легких средней степени тяжести. Пульмонология, 2014, 2: 55-59.Трофименко И.Н., Черняк Б.А. Динамика клинико-функционального статуса и показателей воспаления у больных хронической обструктивной болезнью легких в процессе терапии тиотропием. Мед. совет, 2015, 16: 8-13.Трофименко И.Н., Черняк Б.А. Динамика клинико-функционального статуса и показателей воспаления у больных хронической обструктивной болезнью легких в процессе терапии тиотропием. Мед. совет, 2015, 16: 8-13.Ho spers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet, 2000, 356: 1313-1317.Ho spers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet, 2000, 356: 1313-1317.Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med., 2004, 117: 24-32.Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med., 2004, 117: 24-32.Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc., 2005, 2: 297-304.Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc., 2005, 2: 297-304.Abad Santos F, Novalbos J, Gallego Sandín S, Gálvez Múgica MA. Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors. An. Med. Interna., 2003, 20(4): 201-205.Abad Santos F, Novalbos J, Gallego Sandín S, Gálvez Múgica MA. Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors. An. Med. Interna., 2003, 20(4): 201-205.Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb. Exp. Pharmacol., 2012, 208: 317-341.Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb. Exp. Pharmacol., 2012, 208: 317-341.Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the patho-physiology of asthma and COPD. Respir. Res., 2006, 7: 73.Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the patho-physiology of asthma and COPD. Respir. Res., 2006, 7: 73.O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med., 1996, 154: 876-880.O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med., 1996, 154: 876-880.Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting mus-carinic antagonists tiotropium & glycopyrroni-um against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med., 2016., 118: 96-101.Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting mus-carinic antagonists tiotropium & glycopyrroni-um against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med., 2016., 118: 96-101.Klein G, Kӧhler D, Bauer CP. Standartization of inhalation challenges for measuring the unspecific bronchial inhalation challenge by reservuar-method. Pneumologie, 1991, 45: 60-64.Klein G, Kӧhler D, Bauer CP. Standartization of inhalation challenges for measuring the unspecific bronchial inhalation challenge by reservuar-method. Pneumologie, 1991, 45: 60-64.Стандартизация легочных функциональных тестов. Пер. с англ. под ред. А.Г. Чучалина. Пульмонология (приложение), 1993: 60-69.Стандартизация легочных функциональных тестов. Пер. с англ. под ред. А.Г. Чучалина. Пульмонология (приложение), 1993: 60-69.Gulsvik A, Refvem OK. Ascoring system on respiratory symptoms. Eur. Respir. J., 1988, 1: 428-432.Gulsvik A, Refvem OK. Ascoring system on respiratory symptoms. Eur. Respir. J., 1988, 1: 428-432.Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D et al. Early bronchodilator action of glycopyrronium versus tiotropi-um in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING). Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11: 1425-1434.Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D et al. Early bronchodilator action of glycopyrronium versus tiotropi-um in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING). Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11: 1425-1434.Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm. Med. , 2012, 12: 74.Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm. Med. , 2012, 12: 74.Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther., 2012, 343: 520-8.Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther., 2012, 343: 520-8.Miravitlles M, Beeh K-M, Altman P. Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clin. Invest. (Lond.), 2014, 4(12): 1095–1111.Miravitlles M, Beeh K-M, Altman P. Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clin. Invest. (Lond.), 2014, 4(12): 1095–1111.D’Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res., 2011, 7(12) 156: 2-13.D’Urzo A, Ferguson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res., 2011, 7(12) 156: 2-13.Kerwin E, Hébert J, Gallagher N et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J., 2012, 40: 1106-1114.Kerwin E, Hébert J, Gallagher N et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J., 2012, 40: 1106-1114.

The authors declare that there are no conflicts of interest present.